- Agreement provides Merck with exclusive license to cognitive remediation training programs
- HAPPYneuron will be available for inclusion in Merck’s MSdialog platform for use with Rebif® (interferon beta-1a)
Merck, a leading science and technology company, announced today that the company has entered into an agreement with HAPPYneuron, a subsidiary of SBT Group of France, in which Merck will receive an exclusive license to the company’s cognitive remediation training program for people living with multiple sclerosis (MS). This agreement complements Merck’s broad portfolio of patient support programs in MS and underscores the company’s commitment to leveraging digital platforms and technologies to benefit patients in need.
HAPPYneuron’s cognitive remediation program will be available for inclusion in Merck’s MSdialog platform, when deemed beneficial for a patient by his/her healthcare provider.
MSdialog is currently available in 24 countries. MSdialog with HAPPYneuron will be made available to MS patients initially in a phased roll out beginning in Brazil, Argentina, Israel, Italy, France, and the Netherlands.
Si le fichier PDF ne s'affiche pas ou pour le télécharger, cliquez ici.
Pour consulter le fichier PDF en intégralité, cliquez ici.
|SCIENT.BRAIN TRAIN.||Euronext Paris||5.88 (c)||0.00%||0|